Current Research Studies

MULTICENTER, RANDOMIZED, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED (12-17 YEARS) INCLUDING A SINGLE OPEN-LABEL ARM (6-11 YEARS) STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF CERTOLIZUMAB PEGOL (CZP) IN PEDIATRIC STUDY PARTICIPANTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS (PSO)

CIMCare

  • Condition(s): Other
  • Clinicaltrials.gov ID: NCT04123795

What is the goal of the study?

This Phase 3, multicenter study to evaluate the efficacy, safety, and PK of CZP in pediatric study participants will include 2 cohorts: Cohort A, enrolling study participants aged 12 to 17 years (inclusive), and Cohort B, enrolling study participants aged 6 to 11 years (inclusive). For Cohort A, this study will be randomized, parallel-group, double-blind, and placebo-controlled through Week 16 with one CZP arm; all study participants will receive CZP from Week 16 to Week 52 and through the subsequent 104-week OLE Period. For Cohort B, the study has a single open-label active treatment arm from Week 0 to Week 52 followed by a 104-week OLE.

Who can participate in the study?

Please contact the study team listed below to learn more.

Study Team: